The association between SPINK1 and clinical outcomes in patients with prostate cancer: a systematic review and meta-analysis
Authors:
Open Access
- 1 June 2017
- journal article
- review article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 10, 3123-3130
Abstract
Evidence of the prognostic role of serine peptidase inhibitor Kazal type 1 (SPINK1) in prostate cancer (PCa) is controversial. The aim of this study was, therefore, to evaluate the association between SPINK1 and clinical outcomes in PCa. Searches were made of PubMed, Medline, Embase, and the China Biology Medicine disc (CBMdisc) up to January 2017. The Newcastle–Ottawa Scale was used to assess the risk of bias of included studies. RevMan software was used to perform meta-analysis, and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) method was employed for assessing the quality of the evidence. Ten studies with 17,161 patients were included in the analysis. Random-effect models were adopted for all outcomes with significant heterogeneities. In patients treated with radical prostatectomy, SPINK1 was associated with biochemical recurrence (BCR) (hazard ratio [HR] =1.41, 95% confidence interval [CI]: 1.01–1.97; P=0.04), but not PCa-specific mortality (HR =0.93, 95% CI: 0.33–2.57; P=0.88), and overall survival (OS) (HR =0.89, 95% CI: 0.58–1.35; P=0.57). In metastatic PCa, SPINK1 was significantly associated with castration-resistant PCa-free survival (HR =3.87, 95% CI: 1.87–8.00; P=0.0003) and OS (HR =2.59, 95% CI: 1.16–5.78; P=0.02). However, the quality of the evidence was very low for all study outcome measures. In conclusion, although SPINK1 was not a predictor of PCa mortality or OS among patients who underwent radical prostatectomy, it may have prognostic value in metastatic PCa.Keywords
This publication has 23 references indexed in Scilit:
- Is there any prognostic impact of intraductal carcinoma of prostate in initial diagnosed aggressively metastatic prostate cancer?The Prostate, 2014
- Prostate Cancer SubtyPINg BiomarKers and Outcome: Is Clarity EmERGing?Clinical Cancer Research, 2014
- SPINK1 Protein Expression and Prostate Cancer ProgressionClinical Cancer Research, 2014
- Serine protease inhibitor Kazal type 1 promotes epithelial-mesenchymal transition through EGFR signaling pathway in prostate cancerThe Prostate, 2014
- SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrenceThe Prostate, 2013
- A high-density tissue microarray from patients with clinically localized prostate cancer reveals ERG and TATI exclusivity in tumor cellsProstate Cancer and Prostatic Diseases, 2013
- The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysisCancer Epidemiology, Biomarkers & Prevention, 2012
- Association of SPINK1 Expression and TMPRSS2:ERG Fusion with Prognosis in Endocrine-Treated Prostate CancerClinical Cancer Research, 2010
- The Role of SPINK1 in ETS Rearrangement-Negative Prostate CancersCancer Cell, 2008
- Excretion of a tumor‐associated trypsin inhibitor (TATI) in urine of patients with gynecological malignancyInternational Journal of Cancer, 1983